Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNK-UT009 in Difficult-to-treat Inflammatory Bowel Disease
NCT07416383Phase 1Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2026
- Primary completion
- Dec 2030
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CNK-UT009 in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Maximum Tolerated Dose at 12 weeks and Dose-Limiting Toxicity Rate at 12 weeks. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
CNK-UT009
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07416383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416383.